Dermatomyositis - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 105 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H1 2017, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dermatomyositis - Overview
Dermatomyositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Dermatomyositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dermatomyositis - Companies Involved in Therapeutics Development
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Hope Pharmaceuticals Inc
Idera Pharmaceuticals Inc
KPI Therapeutics Inc
Marathon Pharmaceuticals LLC
MedImmune LLC
Neovacs SA
Novartis AG
Octapharma AG
Pfizer Inc
Dermatomyositis - Drug Profiles
anabasum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalazatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMO-8400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-117 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium thiosulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofacitinib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dermatomyositis - Dormant Projects
Dermatomyositis - Product Development Milestones
Featured News & Press Releases
May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis
May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis
May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis
Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference
Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid
Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum
Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis
Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis
Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
May 13, 2015: Neovacs granted 1.8 million euros in research tax credit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Dermatomyositis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Dermatomyositis - Pipeline by Eli Lilly and Company, H1 2017
Dermatomyositis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Dermatomyositis - Pipeline by Hope Pharmaceuticals Inc, H1 2017
Dermatomyositis - Pipeline by Idera Pharmaceuticals Inc, H1 2017
Dermatomyositis - Pipeline by KPI Therapeutics Inc, H1 2017
Dermatomyositis - Pipeline by Marathon Pharmaceuticals LLC, H1 2017
Dermatomyositis - Pipeline by MedImmune LLC, H1 2017
Dermatomyositis - Pipeline by Neovacs SA, H1 2017
Dermatomyositis - Pipeline by Novartis AG, H1 2017
Dermatomyositis - Pipeline by Octapharma AG, H1 2017
Dermatomyositis - Pipeline by Pfizer Inc, H1 2017
Dermatomyositis - Dormant Projects, H1 2017